Patient Condition
The patient developed right upper limb weakness at the age of 44, and was diagnosed with ALS (limb onset) at the age of 45. At the time of diagnosis, ALSFRS-R was 35, FVC was 80%, and right upper limb muscle strength was grade 4. The progress rate is moderate (0.7 points per month). Enrolled into the phase III clinical trial of NurOwn (MSC-NTF cells).
Treatment Timeline
| Phase | Details | Date |
|---|
| NurOwn stem cell therapy | | |
| Follow-up treatment and evaluation | | |
| long-term follow-up | | |
Treatment Outcome
| before | ALSFRS-R 35, monthly drop 0.7, FVC 80%, right upper limb weakness |
|---|
| after | ALSFRS-R 31 points, 2-year decrease of 4 points (76% delay), FVC 74%, independent daily activities |
|---|
| highlight | NurOwn MSC-NTF cell therapy combined with Ziluzole delayed progression by 76%, with significant anti-inflammatory and neuroprotective effects |
|---|